October 2, 2021

Opinion

Data protection and security is crucial to business sustainability

Lifestyle

Cyberview to further develop Cyberjaya with newly acquired 453.2-acre land

Featured

Bank Negara suspends CCRIS access, no details given for now

Featured

“Penang discriminates Malays?”: Penangites turn the tables on PAS leader!

KUALA LUMPUR, 2 Okt -- Perdana Menteri Datuk Seri Ismail Sabri Yaakob ketika wawancara khas bersama editor kanan media di Menara Parlimen baru-baru ini.?
Beliau berkata pembentangan Belanjawan 2022 akan menumpukan kepada pelaksanaan inisiatif jangka pendek yang dijajarkan dengan dasar dan strategi Rancangan Malaysia Ke-12 (RMK12) bagi mencapai matlamat Keluarga Malaysia - Makmur, Inklusif, Mampan.
--fotoBERNAMA (2021) HAK CIPTA TERPELIHARA

Politics

PM: Political climate calmer now due to the MoU with Opposition

Featured

“M’sia becoming a decaying elitist economy serving kleptomaniacs”

Featured

Is “pay and go free” the new norm for graft cases, Pakatan asks

Featured

Caught on video: Islamic preacher disparages Hindus, Buddhists and Dayaks

Business

MDV continues supporting green tech MSMEs, acquiring new fund worth RM2 bil

FILE PHOTO: An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Handout via REUTERS

Mainstream

Molnupiravir: A potential game-changer in COVID-19 treatment?

Page 1 of 2 1 2 Next

Latest News

Ex-Prasarana CEO questions RM8.5bil Penang LRT deal with Gamuda and SRS

10 hours ago

REHDA institute urges swift urban renewal to protect communities

11 hours ago

Netizens fear e-hailing monopoly after the ban on InDrive and Maxim

12 hours ago

Every supermom deserves a super home and it is spelled HCK Capital

14 hours ago

Defeat for Nurul Izzah may impact Anwar’s leadership in PKR, says Tian Chua

15 hours ago

BUSINESS & BEYOND

About Us

For Advertising Enquiries

+6012 275 0035

Follow Us On

Archives

FREE TOP NEWS DELIVERED

Daily top news delivered to your inbox FREE. Subscribe to enjoy privilege.